Adenosine deaminase capable of acting on DNA and application of adenosine deaminase
By developing a new adenosine deaminase that can act on DNA, the problem that the existing adenosine deaminase cannot act on DNA is solved, and the efficient and precise editing capabilities of the adenine base editing system are achieved.
Patent Information
- Application Number
- CN202410566293.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-12
AI Technical Summary
The existing adenosine deaminase is mainly based on the tRNA deaminase of E. coli and cannot act directly on DNA, limiting the application scenarios and editing efficiency of the adenine base editing system.
A new adenosine deaminase has been developed to enable it to act effectively on DNA through specific amino acid sequence mutation and construction strategies, and is used to build an adenine base editing system to enhance the editing ability of specific DNA sequences.
It realizes efficient base editing of DNA, expands the application scenarios of the adenine base editing system, and improves editing efficiency and accuracy.
Smart Images

Figure CN118931886A_ABST
Abstract
Description
[0001] Priority and related applications
[0002] This application claims priority to Chinese patent application 202310513300.9, filed on May 9, 2023, entitled “Adenosine deaminase capable of acting on DNA and its application”, and all the contents of that application, including the appendix, are incorporated into this application by reference. Technical Field
[0003] The present invention belongs to the field of genetic engineering. Specifically, the present invention relates to an adenosine deaminase that can act on DNA and its application. More specifically, the present invention provides an adenosine deaminase that can act on DNA adenine deoxyribonucleotides, an adenine base editing system based on the adenosine deaminase and its application. A method for base editing a target sequence in the genome of an organism using the base editing system, and a genetically modified organism and its offspring produced by the method. Background Art
[0004] Base editing refers to the process of replacing nucleotides at specific DNA sites through genetic engineering. Base editing is a type of genome editing technology. In plants, many excellent agronomic traits are produced by single nucleotide variations (SNVs); in humans and animals, many genetic diseases are caused by point mutations in functional genes. Base editing technology can be used to modify and transform the genomic DNA of animals, plants, and microorganisms to create new genotypes and obtain target traits that are beneficial to production applications. It can also be used to correct some serious congenital genetic variations in the treatment of genetic diseases. Therefore, base editing has important application prospects in the creation of excellent germplasm and disease treatment.
[0005] Adenine base editor (ABE) is one of the most important base editing systems. In 2017, the ABE base editing system was first reported and successfully achieved efficient base editing in mammalian cells (Gaudelli, NM et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature 551, 464-471 (2017).). The system contains three components: 1) nucleic acid targeting domain, such as Cas9 nickase (nCas9, containing D10A amino acid mutation), 2) adenosine deaminase and 3) sgRNA. The principle of ABE base editing is that under the action of adenosine deaminase, adenine deoxynucleotide (A) is deaminated and converted into the intermediate product inosine deoxynucleotide (I), which is finally converted into guanine deoxynucleotide (G) during cell repair and DNA replication, ultimately resulting in the conversion of AT base pairs on double-stranded DNA to GC base pairs to achieve base editing.
[0006] The key to ABE base editing is to use adenosine deaminase that can act on DNA. However, the substrate of natural adenosine deaminase is RNA rather than DNA, so it cannot deaminize DNA. In order to solve this problem, the researchers used the tRNA adenosine deaminase TadA from Escherichia coli as the chassis protein and carried out multiple rounds of protein evolution. They finally obtained the adenosine deaminase TadA*7.10 that can act on DNA and achieved the conversion of AT base pairs to GC base pairs. Although the researchers introduced some new amino acid mutations based on TadA*7.10 and obtained some new effective mutants, such as TadA-8e, TadA-8s, etc., these adenosine deaminases are still tRNA deaminases derived from Escherichia coli.
[0007] Since the ABE system was first reported in 2017, the adenosine deaminases used in the field have all been based on Escherichia coli TadA, and no other available DNA adenosine deaminase chassis have been reported. Therefore, finding an adenosine deaminase chassis that can act on DNA is extremely important for expanding the existing adenosine base editing system and developing gene editing tools that can accurately manipulate target DNA sequences. Summary of the invention
[0008] In order to solve the problems of the current single type of adenosine deaminase, limited application scenarios, and low editing efficiency, the inventors of this application unexpectedly discovered a new type of adenosine deaminase after a lot of experiments and explorations. The above deaminase can act on adenosine in DNA. Based on this discovery, the inventors developed a new type of adenine base editor, which enriched the application scenarios and choices of adenine base editors.
[0009] Solutions for solving problems
[0010] In the first aspect of the present invention, an adenosine deaminase is provided, wherein the adenosine deaminase is capable of deaminating adenine bases in DNA, and the adenosine deaminase is selected from one or more of the following (i) to (iii):
[0011] (i) comprising an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:4, and which retains the deamination activity of the amino acid sequence shown in SEQ ID NO:4;
[0012] (ii) an amino acid sequence comprising consecutive amino acids added to the C-terminus of the amino acid sequence shown in SEQ ID NO: 4, and which retains the deamination activity of the amino acid sequence shown in SEQ ID NO: 4; or
[0013] (iii) A multimer comprising any two or more amino acid sequences as described in (i) or (ii).
[0014] In some embodiments, in (ii), the adenosine deaminase comprises an amino acid sequence having at least 8 consecutive amino acids added to the C-terminus of SEQ ID NO:4.
[0015] In some embodiments, in (ii), the adenosine deaminase comprises the amino acid sequence shown in SEQ ID NO:5.
[0016] In some embodiments, the adenosine deaminase comprises an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or inserted into the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:5, and retains the deamination activity of the amino acid sequence shown in SEQ ID NO:4.
[0017] In some embodiments, the adenosine deaminase comprises an amino acid sequence having a W71X mutation in SEQ ID NO:4 or SEQ ID NO:5, wherein X is any amino acid except W (tryptophan), preferably, X is Y (tyrosine).
[0018] In some embodiments, the adenosine deaminase comprises an amino acid sequence having an A91X mutation in SEQ ID NO: 4 or SEQ ID NO: 5, wherein X is any amino acid except A (alanine). In some specific embodiments, X is T (threonine).
[0019] In some embodiments, the adenosine deaminase comprises an amino acid sequence having a V80X mutation in SEQ ID NO: 4 or SEQ ID NO: 5, wherein X is any amino acid except V (valine). In some specific embodiments, X is T (threonine).
[0020] In some embodiments, the adenosine deaminase comprises an amino acid sequence having an S122X mutation in SEQ ID NO: 4 or SEQ ID NO: 5, wherein X is any amino acid except S (serine). In some specific embodiments, X is G (glycine).
[0021] In some embodiments, the adenosine deaminase comprises an amino acid sequence having one or more mutations selected from W71Y mutation, A91T mutation, V80T mutation, and S122T mutation in SEQ ID NO:4 or SEQ ID NO:5.
[0022] In some embodiments, the adenosine deaminase comprises an amino acid sequence having a W71Y mutation in SEQ ID NO:4 or SEQ ID NO:5 and a mutation of another adenine deaminase.
[0023] In some specific embodiments, the adenosine deaminase comprises an amino acid sequence having W71Y and A91T mutations in SEQ ID NO:4 or SEQ ID NO:5.
[0024] In some specific embodiments, the adenosine deaminase comprises an amino acid sequence having W71Y and V80T mutations in SEQ ID NO:4 or SEQ ID NO:5.
[0025] In some specific embodiments, the adenosine deaminase comprises an amino acid sequence having W71Y and S122T mutations in SEQ ID NO:4 or SEQ ID NO:5.
[0026] In some embodiments, in (iii), the multimer comprises a dimer consisting of any two amino acid sequences as described in (i) and (ii), and the any two amino acid sequences as described in (i) and (ii) are connected by a linker.
[0027] In some specific embodiments, the linker comprises an amino acid sequence as shown in SEQ ID NO:30.
[0028] In a second aspect of the present invention, provided is the use of the adenosine deaminase according to the first aspect of the present invention for gene editing in an organism or an organism cell, or for preparing a reagent for gene editing in an organism or an organism cell.
[0029] In a third aspect of the present invention, a fusion protein is provided, comprising:
[0030] (a) a nucleic acid targeting domain; and
[0031] (b) an adenosine deamination domain, wherein the adenosine deamination domain comprises at least one polypeptide of the adenosine deaminase according to the first aspect of the present invention.
[0032] In some embodiments, the nucleic acid targeting domain is a TALE, ZFP, or CRISPR effector protein domain.
[0033] In some embodiments, the CRISPR effector protein is selected from Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9, Cas10, Cast10d, Cas12, Cas13, Cas14, CasX, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Csc1, Csc2, Csa5, Csn1, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Cpf1, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csz1, Csx15, Csf1, Csf2, Csf3, Csf4, Cu1966, TraC, and their functional variants or any combination thereof.
[0034] In some embodiments, the nucleic acid targeting domain and the adenosine deamination domain are fused via a linker.
[0035] In some embodiments, the fusion protein further comprises a nuclear localization sequence (NLS).
[0036] In a fourth aspect of the present invention, there is provided a base editing system for modifying a target region of a nucleic acid molecule, comprising:
[0037] i) the adenosine deaminase according to the first aspect of the present invention or the fusion protein according to the third aspect of the present invention, and / or an expression construct containing a nucleotide sequence encoding the adenosine deaminase or the fusion protein.
[0038] In some embodiments, the base editing system further comprises:
[0039] ii) at least one guide RNA and / or at least one expression construct comprising a nucleotide sequence encoding said at least one guide RNA; and / or
[0040] iii) Nuclear localization sequence (NLS).
[0041] In some embodiments, the at least one guide RNA is bound to the nucleic acid targeting domain of the fusion protein, and the guide RNA is directed to at least one target sequence within the target region of the nucleic acid molecule.
[0042] In some embodiments, the guide RNA is 15-100 nucleotides in length and comprises a sequence of at least 10, at least 15, or at least 20 consecutive nucleotides that are complementary to the target sequence.
[0043] In some embodiments, the guide RNA comprises a 15 to 40 contiguous nucleotide sequence that is complementary to the target sequence.
[0044] In some embodiments, the guide RNA is 15-50 nucleotides in length.
[0045] In some embodiments, the nucleic acid molecule is DNA.
[0046] In some embodiments, the nucleic acid molecule is in the genome of an organism.
[0047] In some embodiments, the organism is a prokaryotic organism such as a bacterium; a eukaryotic organism such as a plant, a fungus, or a vertebrate.
[0048] In some embodiments, the vertebrate is a mammal such as a human, mouse, rat, monkey, dog, pig, sheep, cow, or cat.
[0049] In some embodiments, the plant is a crop plant, such as wheat, rice, corn, soybean, sunflower, sorghum, rapeseed, alfalfa, cotton, barley, millet, sugarcane, tomato, kiwifruit, lettuce, tobacco, cassava, or potato.
[0050] In the fifth aspect of the present invention, a base editing method is provided, wherein the base editing method comprises contacting the base editing system described in the fourth aspect of the present invention with a nucleic acid molecule target sequence.
[0051] In some embodiments, the nucleic acid molecule is a double-stranded DNA molecule or a single-stranded DNA molecule.
[0052] In some embodiments, the nucleic acid molecule target sequence comprises a sequence associated with a plant trait or expression.
[0053] In some embodiments, the nucleic acid molecule target sequence comprises a sequence or point mutation associated with a disease or disorder.
[0054] In some embodiments, the base editing system contacts a nucleic acid molecule target sequence to exert a deamination effect, which results in substitution of one or more nucleotides in the target sequence.
[0055] In some embodiments, the target sequence comprises the DNA sequence 5'-MAN-3', wherein M is A, T, C or G; N is A, T, C or G; and wherein the A in the middle of the 5'-MAN-3' sequence is deaminated.
[0056] In some embodiments, the deamination results in the introduction or removal of a splice site.
[0057] In some embodiments, the deamination results in the introduction of a mutation in a gene promoter that results in increased or decreased transcription of a gene operably linked to the gene promoter.
[0058] In some embodiments, the deamination results in the introduction of a mutation in the gene suppressor that results in increased or decreased transcription of a gene operably linked to the gene suppressor.
[0059] In some embodiments, the contacting is performed in vivo or wherein the contacting is performed in vitro.
[0060] In the fifth aspect of the present invention, a method for producing at least one genetically modified cell is provided, comprising introducing the base editing system described in the fourth aspect of the present invention into at least one of the cells, thereby causing one or more nucleotides in the target nucleic acid region in the at least one cell to be replaced, and the one or more nucleotide replacements are A to G replacements.
[0061] In some embodiments, the method further comprises the step of screening the at least one cell for cells having the desired one or more nucleotide substitutions.
[0062] In some embodiments, the base editing system is introduced into cells by a method selected from the following: calcium phosphate transfection, protoplast fusion, electroporation, liposome transfection, microinjection, viral infection (such as baculovirus, vaccinia virus, adenovirus, adeno-associated virus, lentivirus or other virus), N-acetylgalactosamine (GalNAc) mediation, gene gun method, PEG-mediated protoplast transformation, soil Agrobacterium-mediated transformation.
[0063] In some embodiments, the cells are from mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cows, cats; poultry such as chickens, ducks, geese; plants, preferably crop plants, such as wheat, rice, corn, soybeans, sunflowers, sorghum, rapeseed, alfalfa, cotton, barley, millet, sugarcane, tomatoes, kiwifruit, lettuce, tobacco, cassava and potatoes.
[0064] Effects of the Invention
[0065] The present invention provides an adenosine deaminase that can act on DNA, and a gene editing system based on the deaminase and its application, which enriches the application scenarios and choices of adenine base editors and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0066] Figure 1 The amino acid sequence similarity comparison results of QB34, wild-type TadA and TadA-8e are shown.
[0067] Figure 2 Schematic diagram showing the structure of the QB34-based base editor expression construct.
[0068] Figure 3 Showing the editing efficiency of the QB34-based adenine base editor.
[0069] Figure 4 Showing the editing window of the QB34-based adenine base editor at the site 1 target site.
[0070] Figure 5 Showing the editing window of the QB34-based adenine base editor at the site 3 target site.
[0071] Figure 6 Shown is a comparison of the editing efficiencies of TadA- and QB34-based adenine base editors.
[0072] Figure 7 Showing the editing window of the TadA- and QB34-based adenine base editors at the site 1 target site.
[0073] Figure 8 Showing the editing window of the TadA- and QB34-based adenine base editors at the site 3 target site.
[0074] Fig. 9 Showing the editing efficiency of the adenine base editor based on the optimized QB34.
[0075] Fig.10 Showing the editing window of the optimized QB34-based adenine base editor at the site 3 target site.
[0076] Fig.11 Shows the editing window of the adenine base editor based on the QB34C mutant at the site 4 target site.
[0077] Fig.12 Shown is the editing window of the adenine base editor based on the QB34C mutant at the site 10 target site.
[0078] Fig.13 Showing the editing efficiency of adenine base editors based on different dimer forms of the QB34C mutant.
[0079] Fig.14 The editing window of the adenine base editor at the site 1 target site based on different dimer forms of the QB34C mutant is shown.
[0080] Fig.15 Shows the editing window of the adenine base editor at the site 3 target site based on different dimer forms of the QB34C mutant.
[0081] Fig.16 Shown is the editing window of the adenine base editor at the site 10 target site based on different dimer forms of the QB34C mutant. DETAILED DESCRIPTION
[0082] I. Definition
[0083] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology related terms and laboratory operation procedures used herein are terms and routine procedures widely used in the corresponding fields. For example, the standard recombinant DNA and molecular cloning techniques used in the present invention are well known to those skilled in the art and are more fully described in the following documents: Sambrook, J., Fritsch, EF and Maniatis, T., Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter referred to as "Sambrook"). At the same time, in order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.
[0084] As used herein, the term "and / or" encompasses all combinations of items connected by the term, and each combination should be considered to have been listed separately herein. For example, "A and / or B" encompasses "A," "A and B," and "B." For example, "A, B, and / or C" encompasses "A," "B," "C," "A and B," "A and C," "B and C," and "A and B and C."
[0085] When the term "comprising" is used herein to describe a protein or nucleic acid sequence, the protein or nucleic acid may consist of the sequence, or may have additional amino acids or nucleotides at one or both ends of the protein or nucleic acid, but still have the activity described in the present invention. In addition, it is clear to those skilled in the art that the methionine encoded by the start codon at the N-terminus of the polypeptide may be retained in certain practical situations (for example, when expressed in a specific expression system), but it does not substantially affect the function of the polypeptide. Therefore, when describing a specific polypeptide amino acid sequence in the specification and claims of this application, although it may not contain a methionine encoded by a start codon at the N-terminus, a sequence containing the methionine is also covered at this time, and accordingly, its encoding nucleotide sequence may also contain a start codon; and vice versa.
[0086] "Genome" as used herein encompasses not only the chromosomal DNA present in the cell nucleus, but also the organellar DNA present in subcellular components of the cell (eg, mitochondria, plastids).
[0087] As used herein, "organism" includes any organism suitable for genome editing, preferably a eukaryotic organism. Examples of organisms include, but are not limited to, mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cattle, cats; poultry such as chickens, ducks, geese; plants including monocots and dicots, such as rice, corn, wheat, sorghum, barley, soybeans, peanuts, Arabidopsis, etc.
[0088] "Genetically modified organism" or "genetically modified cell" means an organism or cell that contains an exogenous polynucleotide or a modified gene or expression control sequence in its genome. For example, the exogenous polynucleotide can be stably integrated into the genome of the organism or cell and inherited for consecutive generations. The exogenous polynucleotide can be integrated into the genome alone or as part of a recombinant DNA construct. The modified gene or expression control sequence is a sequence in the genome of the organism or cell that contains single or multiple deoxynucleotide substitutions, deletions and additions.
[0089] "Exogenous" with respect to a sequence refers to a sequence that is from a foreign species, or, if from the same species, a sequence that has been significantly altered in composition and / or locus from its native form through deliberate human intervention.
[0090] "Polynucleotide", "nucleic acid sequence", "nucleotide sequence" or "nucleic acid fragment" are used interchangeably and are single-stranded or double-stranded RNA or DNA polymers, optionally containing synthetic, non-natural or altered nucleotide bases. Nucleotides are referred to by their single letter names as follows: "A" is adenosine or deoxyadenosine (RNA or DNA, respectively), "C" represents cytidine or deoxycytidine, "G" represents guanosine or deoxyguanosine, "U" represents uridine, "T" represents deoxythymidine, "R" represents purine (A or G), "Y" represents pyrimidine (C or T), "K" represents G or T, "H" represents A or C or T, "I" represents inosine, and "N" represents any nucleotide. The term "adenine deoxyribonucleotide" and "adenosine" are used interchangeably in the present invention.
[0091] "Polypeptide", "peptide", and "protein" are used interchangeably herein to refer to polymers of amino acid residues. The term applies to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids, as well as to naturally occurring amino acid polymers. The terms "polypeptide", "peptide", "amino acid sequence" and "protein" may also include modified forms, including but not limited to glycosylation, lipid attachment, sulfation, gamma carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation.
[0092] According to the present invention, the amino acid three-letter code and the single-letter code used are as described in J.biol.chem, 243, p3558 (1968).Amino acids and abbreviations and English abbreviations in the present invention are as follows: histidine (His, H); serine (Ser, S); glutamic acid (Glu, E); glutamine (Gln, Q); glycine (Gly, G); threonine (Thr, T); phenylalanine (Phe, F); aspartic acid (Asp, D); tyrosine (Tyr, Y); leucine (Leu, L); isoleucine (Ile, I); arginine (Arg, R); alanine (Ala, A); valine (Val, V); tryptophan (Trp, W); methionine (Met, M); asparagine (Asn, N); cysteine (Cys, C); lysine (Lys, K); proline (Pro, P).
[0093] Sequence "identity" has a meaning recognized in the art, and the percentage of sequence identity between two nucleic acid or polypeptide molecules or regions can be calculated using published techniques. Sequence identity can be measured along the full length of a polynucleotide or polypeptide or along a region of the molecule. (See, for example: Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). Although there are many methods to measure the identity between two polynucleotides or polypeptides, the term "identity" is well known to those of skill (Carrillo, H. & Lipman, D., SIAM J Applied Math 48: 1073 (1988)).
[0094] In peptides or proteins, suitable conservative amino acid substitutions are known to those skilled in the art, and generally can be carried out without changing the biological activity of the resulting molecule. Generally, those skilled in the art recognize that single amino acid substitutions in non-essential regions of a polypeptide do not substantially change biological activity (see, e.g., Watson et al., Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin / Cummings Pub.co., p. 224).
[0095] As used herein, "expression construct" or "construct" refers to a vector, such as a recombinant vector, suitable for expressing a nucleotide sequence of interest in an organism. "Expression" refers to the production of a functional product. For example, expression of a nucleotide sequence may refer to the transcription of the nucleotide sequence (such as transcription to generate mRNA or functional RNA) and / or translation of RNA into a precursor or mature protein.
[0096] The "expression construct" of the present invention can be a linear nucleic acid fragment, a circular plasmid, a viral vector, or, in some embodiments, can be a translatable RNA (such as mRNA).
[0097] An "expression construct" of the present invention may comprise regulatory sequences and a nucleotide sequence of interest from different sources, or regulatory sequences and a nucleotide sequence of interest from the same source but arranged in a manner different from that normally found in nature.
[0098] "Regulatory sequence" and "regulatory element" are used interchangeably and refer to nucleotide sequences located upstream (5' non-coding sequence), in the middle or downstream (3' non-coding sequence) of a coding sequence and affecting the transcription, RNA processing or stability or translation of the relevant coding sequence. Regulatory sequences may include, but are not limited to, promoters, translation leader sequences, introns and polyadenylation recognition sequences.
[0099] "Promoter" refers to a nucleic acid fragment that can control the transcription of another nucleic acid fragment. In some embodiments of the present invention, a promoter is a promoter that can control the transcription of a gene in a cell, whether or not it is derived from the cell. A promoter can be a constitutive promoter or a tissue-specific promoter or a developmentally regulated promoter or an inducible promoter.
[0100] "Constitutive promoter" refers to a promoter that will generally cause a gene to be expressed in most cell types under most circumstances. "Tissue-specific promoter" and "tissue-preferred promoter" are used interchangeably and refer to a promoter that is expressed primarily, but not necessarily exclusively, in one tissue or organ, and may also be expressed in one specific cell or cell type. "Developmentally regulated promoter" refers to a promoter whose activity is determined by developmental events. "Inducible promoter" selectively expresses an operably linked DNA sequence in response to endogenous or exogenous stimuli (environmental, hormonal, chemical signals, etc.).
[0101] As used herein, the term "operably linked" refers to the connection of a regulatory element (e.g., but not limited to, a promoter sequence, a transcription termination sequence, etc.) to a nucleic acid sequence (e.g., a coding sequence or an open reading frame) such that transcription of the nucleotide sequence is controlled and regulated by the transcription regulatory element. Techniques for operably linking a regulatory element region to a nucleic acid molecule are known in the art.
[0102] "Introducing" a nucleic acid molecule (e.g., a plasmid, a linear nucleic acid fragment, RNA, etc.) or a protein into an organism refers to transforming an organism cell with the nucleic acid or protein so that the nucleic acid or protein can function in the cell. "Transformation" as used in the present invention includes stable transformation and transient transformation.
[0103] "Stable transformation" refers to the introduction of an exogenous nucleotide sequence into a genome, resulting in the stable inheritance of the exogenous nucleotide sequence. Once stably transformed, the exogenous nucleic acid sequence is stably integrated into the genome of the organism and any successive generations thereof.
[0104] "Transient transformation" refers to the introduction of a nucleic acid molecule or protein into a cell to perform its function without the stable inheritance of the exogenous nucleotide sequence. In transient transformation, the exogenous nucleic acid sequence is not integrated into the genome.
[0105] "Trait" refers to a physiological, morphological, biochemical, or physical characteristic of a cell or organism.
[0106] "Agronomic traits" specifically refer to measurable indicator parameters of crop plants, including but not limited to: leaf green, grain yield, growth rate, total biomass or accumulation rate, fresh weight at maturity, dry weight at maturity, fruit yield, seed yield, plant total nitrogen content, fruit nitrogen content, seed nitrogen content, plant vegetative tissue nitrogen content, plant total free amino acid content, fruit free amino acid content, seed free amino acid content, plant vegetative tissue free amino acid content, plant total protein content, fruit protein content, seed protein content, plant vegetative tissue protein content, herbicide resistance and drought resistance, nitrogen absorption, root lodging, harvest index, stem lodging, plant height, ear height, ear length, disease resistance, cold resistance, salt resistance and tillering number, etc.
[0107] 2. Adenosine deaminase
[0108] The term "deaminase" refers to a protein or enzyme that catalyzes a deamination reaction. In some embodiments, the deaminase is an adenosine deaminase, which catalyzes the hydrolytic deamination of adenine or adenosine. In some embodiments, the deaminase or deaminase domain is an adenosine deaminase, which catalyzes the hydrolytic deamination of adenosine or deoxyadenosine to inosine or deoxyinosine, respectively. In some embodiments, the adenosine deaminase catalyzes the hydrolytic deamination of adenine or adenosine in deoxyribonucleic acid (DNA). The adenosine deaminase provided herein (e.g., engineered adenosine deaminase, evolved adenosine deaminase) can be from any organism, such as bacteria. In some embodiments, the deaminase is a variant of a naturally occurring deaminase from an organism. In some embodiments, the deaminase does not exist in nature.
[0109] The term "dimer" refers to substances of the same or same type that appear in pairs and may have properties or functions that are not present in a single state. In some embodiments, a dimer refers to two identical or different adenosine deaminases. In some embodiments, the dimers are connected by a linker. In some embodiments, the linker is a polypeptide.
[0110] In some embodiments, the adenosine deaminase comprises an amino acid sequence having at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even 100% sequence identity to SEQ ID NO:4, and it retains the deamination activity of the amino acid sequence shown in SEQ ID NO:4.
[0111] In some embodiments, the adenosine deaminase comprises an amino acid sequence that adds or subtracts consecutive amino acids at the C-terminus or N-terminus of SEQ ID NO: 4 without changing the function of the adenosine deaminase to deaminize adenine of deoxyadenosine in DNA (e.g., retaining the deamination activity of the amino acid sequence shown in SEQ ID NO: 4).
[0112] In some embodiments, the adenosine deaminase comprises an amino acid sequence having at least 8 consecutive amino acids added to the C-terminus of SEQ ID NO:4.
[0113] In some exemplary embodiments, the adenosine deaminase comprises the amino acid sequence shown in SEQ ID NO:5.
[0114] In some embodiments, the adenosine deaminase comprises an amino acid sequence having a W71X mutation in SEQ ID NO:4 or SEQ ID NO:5, wherein X is any amino acid except W (tryptophan). In some embodiments, X is Y (tyrosine). In some exemplary embodiments, the adenosine deaminase comprises an amino acid sequence as shown in SEQ ID NO:6.
[0115] In some embodiments, the adenosine deaminase comprises an amino acid sequence having an A91X mutation in SEQ ID NO: 4 or SEQ ID NO: 5, wherein X is any amino acid except A (alanine). In some embodiments, X is T (threonine).
[0116] In some embodiments, the adenosine deaminase comprises an amino acid sequence having a V80X mutation in SEQ ID NO: 4 or SEQ ID NO: 5, wherein X is any amino acid except V (valine). In some embodiments, X is T (threonine).
[0117] In some embodiments, the adenosine deaminase comprises an amino acid sequence having an S122X mutation in SEQ ID NO: 4 or SEQ ID NO: 5, wherein X is any amino acid except S (serine). In some embodiments, X is G (glycine).
[0118] In some embodiments, the adenosine deaminase comprises an amino acid sequence having one or more mutations selected from W71Y mutation, A91T mutation, V80T mutation, and S122T mutation in SEQ ID NO:4 or SEQ ID NO:5.
[0119] In some embodiments, the adenosine deaminase comprises an amino acid sequence having a W71Y mutation in SEQ ID NO:4 or SEQ ID NO:5 and a mutation of another adenine deaminase.
[0120] In some embodiments, the adenosine deaminase comprises an amino acid sequence having W71Y and A91T mutations in SEQ ID NO: 4 or SEQ ID NO: 5. In some exemplary embodiments, the adenosine deaminase comprises an amino acid sequence as shown in SEQ ID NO: 7.
[0121] In some embodiments, the adenosine deaminase comprises an amino acid sequence having W71Y and V80T mutations in SEQ ID NO: 4 or SEQ ID NO: 5. In some exemplary embodiments, the adenosine deaminase comprises an amino acid sequence as shown in SEQ ID NO: 8.
[0122] In some embodiments, the adenosine deaminase comprises an amino acid sequence having W71Y and S122T mutations in SEQ ID NO: 4 or SEQ ID NO: 5. In some exemplary embodiments, the adenosine deaminase comprises an amino acid sequence as shown in SEQ ID NO: 9.
[0123] In some embodiments, the adenosine deaminase comprises a polymer consisting of any two or more of the amino acid sequences of the adenosine deaminase.
[0124] In some embodiments, the adenosine deaminase comprises a dimer composed of any two of the adenosine deaminases (ie, any two amino acid sequences of the adenosine deaminase).
[0125] In some embodiments, the dimer is formed by any two adenosine deaminases (i.e., any two amino acid sequences of the adenosine deaminases) connected by a linker. In some embodiments, the linker is a polypeptide chain of 32 amino acids (32aa), and the linker comprises the amino acid sequence shown in SEQ ID NO:30.
[0126] In some exemplary embodiments, the adenosine deaminase comprises an amino acid sequence as shown in any one of SEQ ID NOs: 10-13.
[0127] 3. Base editing fusion protein containing adenosine deaminase
[0128] In one aspect, the present application relates to the use of the adenosine deaminase of the present invention for gene editing in an organism or an organism cell, or the use of the adenosine deaminase of the present invention in the preparation of a reagent for gene editing in an organism or an organism cell. In some embodiments, the use may be a use in disease diagnosis and treatment methods. In other embodiments, the use may be a use in non-disease diagnosis and treatment methods.
[0129] In another aspect, the present invention provides a fusion protein comprising: (a) a nucleic acid targeting domain; and (b) an adenosine deamination domain, wherein the adenosine deamination domain comprises at least one polypeptide of an adenosine deaminase of the present invention.
[0130] In the embodiments herein, "fusion protein", "base editing fusion protein" and "base editor" are used interchangeably and refer to a reagent comprising a polypeptide capable of modifying a base (e.g., A, T, C, G, or U). In some embodiments, a base editor is capable of deaminating a base within a nucleic acid. In some embodiments, a base editor is capable of deaminating a base within a DNA molecule. In some embodiments, a base editor is capable of deaminating adenine (A) in DNA.
[0131] As used herein, "nucleic acid targeting domain" refers to a domain that can mediate the attachment of the base editing fusion protein to a specific target sequence in the genome in a sequence-specific manner (e.g., by a guide RNA). In some embodiments, the nucleic acid targeting domain may include one or more zinc finger protein domains (ZFP) or transcription factor effector domains (TALE) for a specific target sequence. In some embodiments, the nucleic acid targeting domain comprises at least one (e.g., one) CRISPR effector protein (CRISPR effector) polypeptide.
[0132] "Zinc finger protein domain (ZFP)" usually contains 3-6 individual zinc finger repeat sequences, each of which can recognize a unique sequence of, for example, 3 bp. By combining different zinc finger repeat sequences, different genomic sequences can be targeted.
[0133] A "transcription activator-like effector domain" is a DNA binding domain of a transcription activator-like effector (TALE). TALEs can be engineered to bind to almost any desired DNA sequence.
[0134] As used herein, the term "CRISPR effector protein" generally refers to a nuclease (CRISPR nuclease) or a functional variant thereof present in a naturally occurring CRISPR system. The term encompasses any effector protein based on the CRISPR system that is capable of achieving sequence-specific targeting within a cell.
[0135] As used herein, a "functional variant" with respect to a CRISPR nuclease means that it at least retains the sequence-specific targeting ability mediated by the guide RNA. Preferably, the functional variant is a variant in which the nuclease is inactivated, i.e., it lacks double-stranded nucleic acid cleavage activity. However, CRISPR nucleases lacking double-stranded nucleic acid cleavage activity also encompass nickases, which form a nick in a double-stranded nucleic acid molecule but do not completely cut off the double-stranded nucleic acid. In some preferred embodiments of the present invention, the CRISPR effector protein of the present invention has nickase activity. In some embodiments, the functional variant recognizes a different PAM (protospacer adjacent motif) sequence relative to the wild-type nuclease.
[0136] "CRISPR effector protein" can be derived from Cas9 nuclease, including Cas9 nuclease or its functional variant. The Cas9 nuclease can be a Cas9 nuclease from different species, such as spCas9 from Streptococcus pyogenes (S.pyogenes) or SaCas9 derived from Staphylococcus aureus (S.aureus). "Cas9 nuclease" and "Cas9" are used interchangeably herein, referring to an RNA-guided nuclease including a Cas9 protein or a fragment thereof (e.g., a protein comprising an active DNA cleavage domain of Cas9 and / or a gRNA binding domain of Cas9). Cas9 is a component of the CRISPR / Cas (clustered regularly interspaced short palindromic repeats and related systems) genome editing system, which can target and cut DNA target sequences under the guidance of guide RNA to form DNA double-strand breaks (DSBs). An exemplary amino acid sequence of wild-type SpCas9 is shown in SEQ ID NO: 16.
[0137] Useful "CRISPR effector proteins" can also be derived from Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9, Cas10, Cast10d, Cas12, Cas13, Cas14, CasX, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (or CasA), Cse2 (or CasB), Cse3 (or CasE), Nucleases such as Cse4 (or CasC), Csc1, Csc2, Csa5, Csn1, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Cpf1, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csz1, Csx15, Csf1, Csf2, Csf3, Csf4, Cu1966 and TraC, for example, include these nucleases or functional variants thereof. Wherein the TraC nuclease refers to the disclosure in PCT / CN2023 / 097783 (Publication No. WO / 2023 / 232109), which is incorporated herein by reference.
[0138] The "CRISPR effector protein" can also be derived from a Cpf1 nuclease, including a Cpf1 nuclease or a functional variant thereof. The Cpf1 nuclease can be a Cpf1 nuclease from different species, such as a Cpf1 nuclease from Francisella novicida U112, Acidaminococcus sp. BV3L6, and Lachnospiraceae bacterium ND2006.
[0139] In some embodiments, the CRISPR effector protein can be a nuclease-inactivated Cas9. The DNA cleavage domain of the Cas9 nuclease is known to contain two subdomains: the HNH nuclease subdomain and the RuvC subdomain. The HNH subdomain cuts the strand complementary to the gRNA, while the RuvC subdomain cuts the non-complementary strand. Mutations in these subdomains can inactivate the nuclease activity of Cas9, forming a "nuclease-inactivated Cas9". The nuclease-inactivated Cas9 still retains the DNA binding ability guided by the gRNA.
[0140] The nuclease-inactivated Cas9 of the present invention can be derived from Cas9 of different species, for example, derived from Streptococcus pyogenes (S. pyogenes) Cas9 (SpCas9), or derived from Staphylococcus aureus (S. aureus) Cas9 (SaCas9). Mutating the HNH nuclease subdomain and the RuvC subdomain of Cas9 (for example, comprising mutations D10A and H840A) simultaneously inactivates the nuclease of Cas9 and becomes nuclease-inactivated Cas9 (dCas9). Mutating and inactivating one of the subdomains can make Cas9 have nickase activity, that is, obtaining Cas9 nickase (nCas9), for example, nCas9 with only mutation D10A.
[0141] In some embodiments of the present invention, the adenosine deamination domain in the fusion protein is capable of converting the adenosine of the single-stranded DNA generated during the formation of the fusion protein-guide RNA-DNA complex into inosine I, and then achieving base substitution from A to G through base mismatch repair.
[0142] In some embodiments of the invention, the nucleic acid targeting domain and the adenosine deamination domain are fused via a linker.
[0143] As used herein, a "linker" can be a non-functional amino acid sequence of 1-50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 20-25, 25-50) or more amino acids in length, without a secondary or higher structure. For example, the linker can be a flexible linker.
[0144] In some embodiments of the present invention, the fusion protein of the present invention may further include a nuclear localization sequence (NLS). In general, one or more NLS in the fusion protein should have sufficient strength to drive the fusion protein in the nucleus of the cell to accumulate in an amount that can realize its base editing function. In general, the intensity of nuclear localization activity is determined by the number, position, one or more specific NLS used in the fusion protein, or a combination of these factors.
[0145] In some embodiments of the present invention, the NLS of the fusion protein of the present invention can be located at the N-terminus and / or the C-terminus. In some embodiments of the present invention, the NLS of the fusion protein of the present invention can be located between the adenine deamination domain and the nucleic acid targeting domain. In some embodiments, the fusion protein comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLS. In some embodiments, the fusion protein is included in or close to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLS at the N-terminus. In some embodiments, the fusion protein is included in or close to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLS at the C-terminus. In some embodiments, the polypeptide comprises a combination of these, such as one or more NLSs included at the N-terminus and one or more NLSs at the C-terminus. When there is more than one NLS, each can be selected to be independent of other NLSs.
[0146] In general, NLS consists of one or more short sequences of positively charged lysine or arginine exposed on the surface of the protein, but other types of NLS are also known. Non-limiting examples of NLS include: KKRKV (SEQ ID NO: 33), PKKKRKV (SEQ ID NO: 34), KRPAATKKAGQAKKKK (SEQ ID NO: 35) or MKRTADGSEFEPKKKRKV (SEQ ID NO: 36).
[0147] In addition, depending on the DNA location to be edited, the fusion protein of the present invention may also include other localization sequences, such as cytoplasmic localization sequences, chloroplast localization sequences, mitochondrial localization sequences, etc.
[0148] 4. Genome Editing System
[0149] In another aspect, the present invention provides a base editing system comprising: i) an adenosine deaminase or a base editing fusion protein of the present invention, and / or an expression construct containing a nucleotide sequence encoding the adenosine deaminase or the base editing fusion protein.
[0150] In some embodiments, the base editing system is used to modify a target region of a nucleic acid.
[0151] In some embodiments, the base editing system further comprises ii) at least one guide RNA and / or at least one expression construct comprising a nucleotide sequence encoding the at least one guide RNA. However, one skilled in the art will appreciate that if the base editing fusion protein is not based on a CRISPR effector protein, the system may not require a guide RNA or an expression construct encoding the same.
[0152] In some embodiments, the at least one guide RNA can bind to the nucleic acid targeting domain of the fusion protein. In some embodiments, the guide RNA is directed to at least one target sequence within the nucleic acid target region.
[0153] As used herein, a "base editing system" refers to a combination of components required for base editing a nucleic acid sequence, such as a genomic sequence in a cell or an organism. The individual components of the system, such as adenosine deaminase, a base editing fusion protein, and one or more guide RNAs, may exist independently of each other, or may exist in any combination as a composition.
[0154] In some embodiments, it comprises an adenosine deaminase of the present invention or a fusion protein of the present invention and a guide RNA that can bind to a nucleic acid-targeting binding protein.
[0155] As used herein, "guide RNA" and "gRNA" are used interchangeably and refer to an RNA molecule that can form a complex with a CRISPR effector protein and can target the complex to a target sequence due to a certain homology with the target sequence. The guide RNA targets the target sequence by base pairing with the complementary strand of the target sequence. For example, the gRNA used by the Cas9 nuclease or its functional variant is generally composed of crRNA and tracrRNA molecules that are partially complementary to form a complex, wherein the crRNA contains a guide sequence (also called a seed sequence) that has sufficient homology to the target sequence so as to hybridize with the complementary strand of the target sequence and guide the CRISPR complex (Cas9+crRNA+tracrRNA) to specifically bind to the target sequence sequence. However, it is known in the art that a single guide RNA (sgRNA) can be designed, which contains the features of crRNA and tracrRNA at the same time. The gRNA used by the Cpf1 nuclease or its functional variant is generally composed of only mature crRNA molecules, which can also be referred to as gRNA. It is within the capabilities of those skilled in the art to design suitable gRNAs based on other CRISPR nucleases used and target sequences to be edited.
[0156] In some embodiments, the guide RNA is 15-100 nucleotides in length and comprises a sequence of at least 10, at least 15, or at least 20 consecutive nucleotides that are complementary to the target sequence.
[0157] In some embodiments, the guide RNA comprises a 15 to 40 contiguous nucleotide sequence that is complementary to the target sequence.
[0158] In some embodiments, the guide RNA is 15-50 nucleotides in length.
[0159] In some embodiments, the target sequence is a DNA sequence.
[0160] In some embodiments, wherein the target sequence is in the genome of an organism. In some embodiments, wherein the organism is a prokaryote. In some embodiments, wherein the prokaryote is a bacterium. In some embodiments, wherein the organism is a eukaryote. In some embodiments, wherein the organism is a plant or a fungus. In some embodiments, wherein the organism is a vertebrate. In some embodiments, wherein the vertebrate is a mammal. In some embodiments, wherein the mammal is a mouse, a rat or a human. In some embodiments, wherein the organism is a cell. In some embodiments, wherein the cell is a mouse cell, a rat cell or a human cell. In some embodiments, wherein the cell is a HEK-293T cell.
[0161] In some embodiments, after the base editing system of the present invention is introduced into the cell, the base editing fusion protein and the guide RNA are able to form a complex, and the complex specifically targets the target sequence under the mediation of the guide RNA, and causes one or more A in the target sequence to be replaced by G.
[0162] In some embodiments, the at least one guide RNA can be directed to a target sequence on a sense strand (e.g., a protein coding strand) and / or an antisense strand located in a genomic target nucleic acid region. When the guide RNA targets the sense strand (e.g., a protein coding strand), the base editing composition of the present invention can cause one or more A in the target sequence on the sense strand (e.g., a protein coding strand) to be replaced by G. When the guide RNA targets the antisense strand, the base editing composition of the present invention can cause one or more T in the target sequence on the sense strand (e.g., a protein coding strand) to be replaced by C.
[0163] In order to obtain efficient expression in cells, in some embodiments of the present invention, the nucleotide sequence encoding the adenosine deaminase or base editing fusion protein is codon-optimized for the organism whose genome is to be modified.
[0164] Codon optimization refers to a method of modifying a nucleic acid sequence to enhance expression in a host cell of interest by replacing at least one codon of the native sequence (e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more codons) with codons that are more frequently or most frequently used in the genes of the host cell while maintaining the native amino acid sequence. Different species exhibit specific preferences for certain codons for specific amino acids. Codon bias (differences in codon usage between organisms) is often correlated with the efficiency of translation of messenger RNA (mRNA), which in turn is believed to depend on the nature of the codons being translated and the availability of specific transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell generally reflects the codons most frequently used for peptide synthesis. Therefore, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example at www.kazusa.orjp / codon / The codon usage tables are tabulated from the international DNA sequence databases: status for the year 2000. Nucl. Acids Res., 28: 292 (2000).
[0165] Organisms that can be subjected to genome modification by the base editing system of the present invention include any organisms suitable for base editing, preferably eukaryotic organisms. Examples of organisms include, but are not limited to, mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cattle, cats; poultry such as chickens, ducks, geese; plants, including monocots and dicots, for example, the plants are crop plants, including but not limited to wheat, rice, corn, soybeans, sunflowers, sorghum, rapeseed, alfalfa, cotton, barley, millet, sugarcane, tomatoes, kiwis, lettuce, tobacco, cassava and potatoes.
[0166] 5. Base Editing Methods
[0167] In another aspect, the present invention provides a base editing method, which comprises contacting the base editing system of the present invention with a nucleic acid molecule target sequence.
[0168] In some embodiments, the nucleic acid molecule is a DNA molecule. In some preferred embodiments, the nucleic acid molecule is a double-stranded DNA molecule or a single-stranded DNA molecule.
[0169] In some embodiments, the nucleic acid molecule target sequence comprises a sequence associated with a plant trait or expression.
[0170] In some embodiments, the nucleic acid molecule target sequence comprises a sequence or point mutation associated with a disease or disorder.
[0171] In some embodiments, the base editing system contacts a nucleic acid molecule target sequence to exert a deamination effect, and the deamination effect causes one or more nucleotides of the target sequence to be replaced.
[0172] In some embodiments, the target sequence comprises the DNA sequence 5'-MAN-3', wherein M is A, T, C or G; N is A, T, C or G; and wherein the A in the middle of the 5'-MAN-3' sequence is deaminated.
[0173] In some embodiments, the deamination results in the introduction or removal of a splice site.
[0174] In some embodiments, the deamination results in the introduction of a mutation in a gene promoter, the mutation resulting in increased or decreased transcription of a gene operably linked to the gene promoter.
[0175] In some embodiments, wherein the deamination results in the introduction of a mutation in the gene suppressor, the mutation results in increased or decreased transcription of a gene operably linked to the gene suppressor.
[0176] In some embodiments, the contacting is performed in vivo.
[0177] In some embodiments, the contacting is performed in vitro.
[0178] VI. Methods for Producing Genetically Modified Cells
[0179] On the other hand, the present invention also provides a method for producing at least one genetically modified cell, comprising introducing the base editing system of the present invention into at least one of the cells, thereby causing one or more nucleotide substitutions within the target nucleic acid region in the at least one cell. In some embodiments, the one or more nucleotide substitutions are A to G substitutions.
[0180] In some embodiments, the method further comprises the step of screening the at least one cell for cells having the desired one or more nucleotide substitutions.
[0181] In some embodiments, the methods of the invention are performed in vitro. For example, the cells are isolated cells, or cells in isolated tissues or organs.
[0182] In another aspect, the present invention also provides a genetically modified organism comprising a genetically modified cell or a progeny cell thereof produced by the method of the present invention. Preferably, the genetically modified cell or a progeny cell thereof has a desired one or more nucleotide substitutions.
[0183] In the present invention, the target nucleic acid region to be modified can be located at any position of the genome, for example, in a functional gene such as a protein coding gene, or, for example, in a gene expression regulatory region such as a promoter region or an enhancer region, thereby achieving modification of the gene function or modification of gene expression. In some embodiments, the desired nucleotide substitution results in a desired gene function modification or gene expression modification.
[0184] In some embodiments, the target nucleic acid region is related to the proterties of the cell or organism. In some embodiments, the mutation in the target nucleic acid region causes a change in the proterties of the cell or organism. In some embodiments, the target nucleic acid region is located in the coding region of protein. In some embodiments, the function-related motif or domain of the target nucleic acid region encoding protein. In some preferred embodiments, one or more nucleotides in the target nucleic acid region replace the amino acid replacement in the amino acid sequence of the protein. In some embodiments, the one or more nucleotides replace the change in the function of the protein.
[0185] In the method of the present invention, the base editing system can be introduced into cells by various methods well known to those skilled in the art.
[0186] Methods that can be used to introduce the base editing system of the present invention into cells include, but are not limited to, calcium phosphate transfection, protoplast fusion, electroporation, liposome transfection, microinjection, viral infection (such as baculovirus, vaccinia virus, adenovirus, adeno-associated virus, lentivirus and other viruses), N-acetylgalactosamine (GalNAc) mediation, gene gun method, PEG-mediated protoplast transformation, and soil Agrobacterium-mediated transformation.
[0187] Cells that can be base edited by the methods of the present invention can be from, for example, mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cattle, cats; poultry such as chickens, ducks, geese; plants, including monocots and dicots, preferably crop plants, including but not limited to wheat, rice, corn, soybeans, sunflowers, sorghum, rapeseed, alfalfa, cotton, barley, millet, sugarcane, tomatoes, kiwis, lettuce, tobacco, cassava and potatoes.
[0188] 7. Application in plants
[0189] The base editing fusion proteins, base editing systems and methods for producing genetically modified cells of the present invention are particularly suitable for genetically modifying plants. Preferably, the plants are crop plants, including but not limited to wheat, rice, corn, soybean, sunflower, sorghum, rapeseed, alfalfa, cotton, barley, millet, sugarcane, tomato, kiwi, lettuce, tobacco, cassava and potato.
[0190] In another aspect, the present invention provides a method for producing a genetically modified plant, comprising introducing the base editing system of the present invention into at least one of the plants, thereby causing one or more nucleotide substitutions within a target nucleic acid region in the genome of the at least one plant.
[0191] In some embodiments, the method further comprises screening the at least one plant for plants having the desired one or more nucleotide substitutions.
[0192] In the method of the present invention, the base editing composition can be introduced into plants by various methods well known to those skilled in the art. Methods that can be used to introduce the base editing system of the present invention into plants include, but are not limited to, gene gun method, PEG-mediated protoplast transformation, soil Agrobacterium-mediated transformation, plant virus-mediated transformation, pollen tube channel method, and ovary injection method. Preferably, the base editing composition is introduced into the plant by transient transformation.
[0193] In the method of the present invention, the modification of the target sequence can be achieved by simply introducing or producing the base editing fusion protein and guide RNA in plant cells, and the modification can be stably inherited without the need to stably transform the exogenous polynucleotides encoding the components of the base editing system into plants. This avoids the potential off-target effects of the stably existing (continuously produced) base editing composition and also avoids the integration of exogenous nucleotide sequences into the plant genome, thereby having higher biosafety.
[0194] In some preferred embodiments, the introduction is performed in the absence of selection pressure, thereby avoiding integration of the exogenous nucleotide sequence into the plant genome.
[0195] In some embodiments, the introduction includes transforming the base editing system of the present invention into isolated plant cells or tissues, and then regenerating the transformed plant cells or tissues into complete plants. Preferably, the regeneration is carried out in the absence of selection pressure, that is, no selection agent for the selection gene carried on the expression vector is used during tissue culture. Not using a selection agent can improve the regeneration efficiency of the plant and obtain a modified plant that does not contain exogenous nucleotide sequences.
[0196] In other embodiments, the base editing system of the present invention can be transformed into specific parts of the whole plant, such as leaves, stem tips, pollen tubes, panicles or hypocotyls. This is particularly suitable for the transformation of plants that are difficult to regenerate through tissue culture.
[0197] In some embodiments of the invention, the in vitro expressed protein and / or in vitro transcribed RNA molecule (e.g., the expression construct is an in vitro transcribed RNA molecule) is directly transformed into the plant. The protein and / or RNA molecule can achieve base editing in plant cells and then be degraded by the cells, avoiding the integration of exogenous nucleotide sequences in the plant genome.
[0198] Therefore, in some embodiments, genetic modification and breeding of plants using the methods of the present invention can obtain plants whose genomes have no exogenous polynucleotides integrated, ie, non-transgenic (transgene-free) modified plants.
[0199] In some embodiments of the invention, the modified target nucleic acid region is associated with a plant trait such as an agronomic trait, whereby the one or more nucleotide substitutions result in the plant having an altered (preferably improved) trait, such as an agronomic trait, relative to a wild-type plant.
[0200] In some embodiments, the method further comprises the step of screening plants for desired one or more nucleotide substitutions and / or desired traits, such as agronomic traits.
[0201] In some embodiments of the present invention, the method further comprises obtaining offspring of the genetically modified plant. Preferably, the genetically modified plant or its offspring has a desired one or more nucleotide substitutions and / or a desired trait such as an agronomic trait.
[0202] On the other hand, the present invention also provides a genetically modified plant or its offspring or its part, wherein the plant is obtained by the above-mentioned method of the present invention. In some embodiments, the genetically modified plant or its offspring or its part is non-transgenic. Preferably, the genetically modified plant or its offspring has a desired genetic modification and / or a desired trait such as an agronomic trait.
[0203] In another aspect, the present invention also provides a plant breeding method, comprising hybridizing a first genetically modified plant comprising one or more nucleotide substitutions in a target nucleic acid region obtained by the above-mentioned method of the present invention with a second plant not containing the one or more nucleotide substitutions, thereby introducing the one or more nucleotide substitutions into the second plant. Preferably, the first genetically modified plant has a desired trait such as an agronomic trait.
[0204] 8. Therapeutic Application
[0205] The present invention also covers the use of the base editing system of the present invention in the treatment of diseases or the preparation of drugs for the treatment of diseases.
[0206] By modifying the disease-related genes through the base editing system of the present invention, it is possible to achieve upregulation, downregulation, inactivation, activation or mutation correction of the disease-related genes, thereby achieving disease prevention and / or treatment. For example, the target nucleic acid region described in the present invention may be located in the protein coding region of the disease-related gene, or, for example, may be located in a gene expression regulatory region such as a promoter region or an enhancer region, so that the disease-related gene function modification or the disease-related gene expression modification can be achieved. Therefore, the modified disease-related genes described herein include modification of the disease-related genes themselves (e.g., protein coding regions), and also include modification of their expression regulatory regions (e.g., promoters, enhancers, introns, etc.).
[0207] "Disease-related" gene refers to any gene that produces a transcription or translation product at an abnormal level or in an abnormal form in cells derived from tissues affected by the disease, compared to tissues or cells of non-disease controls. In the case where the altered expression is related to the appearance and / or progression of the disease, it can be a gene expressed at an abnormally high level; it can be a gene expressed at an abnormally low level. Disease-related genes also refer to genes with one or more mutations or genetic variations that are directly responsible or unbalanced with one or more genes responsible for the etiology of the disease. The mutation or genetic variation is, for example, a single nucleotide variation (SNV). The transcribed or translated product can be known or unknown, and can be at normal or abnormal levels.
[0208] Therefore, the present invention also provides a method for treating a disease in a subject in need thereof, comprising delivering an effective amount of a base editing system of the present invention to the subject to modify a gene associated with the disease (e.g., deaminating mitochondrial DNA by a fusion protein or multiple fusion proteins). The present invention also provides the use of a base editing system in the preparation of a pharmaceutical composition for treating a disease in a subject in need thereof, wherein the base editing system is used to modify a gene associated with the disease. The present invention also provides a pharmaceutical composition for treating a disease in a subject in need thereof, comprising a base editing system of the present invention, and an optional pharmaceutically acceptable carrier, wherein the base editing system is used to modify a gene associated with the disease.
[0209] In some embodiments, the fusion protein or base editing system described in the present invention is used to introduce point mutations into nucleic acids by deaminating target nuclear bases (e.g., A residues). In some embodiments, the deamination of target nuclear bases leads to the correction of genetic defects, such as in point mutations that cause loss of function in gene products. In some embodiments, genetic defects are associated with diseases or disorders (e.g., lysosomal storage diseases or metabolic diseases, such as, for example, type I diabetes). In some embodiments, the methods provided herein can be used to introduce inactivating point mutations into genes or alleles encoding gene products associated with diseases or disorders.
[0210] In some embodiments, the purpose of the scheme described in the present invention is to restore the function of dysfunctional genes via genome editing. The nucleobase editing proteins provided herein are used for gene editing of human cells in vitro, such as correcting disease-related mutations in human cell cultures. The nucleobase editing proteins provided herein, such as fusion proteins containing nucleic acid editable DNA proteins (e.g., CRISPR effector proteins Cas9) and adenosine deaminase domains, can be used to correct any single-point G to A or C to T mutations. In the first case, the A of the mutant is corrected for mutation by deamination, and in the latter case, the A paired with the mutant T is corrected for mutation by deamination and a subsequent round of replication.
[0211] In some embodiments, the purpose of the scheme described in the present invention is to treat diseases associated with or caused by point mutations, which can be corrected by the DNA base editing fusion protein provided herein. In some embodiments, the disease is a proliferative disease. In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease.
[0212] In some embodiments, the invention describes a method for treating mitochondrial diseases or disorders. As used herein, "mitochondrial diseases" refer to diseases caused by abnormal mitochondria, such as mitochondrial gene mutations, enzyme pathways, etc. Examples of diseases include, but are not limited to: neurological diseases, loss of motor control, muscle weakness and pain, gastrointestinal diseases and dysphagia, poor growth, heart disease, liver disease, diabetes, respiratory complications, epilepsy, vision / hearing problems, lactic acidosis, developmental delays, and susceptibility to infection.
[0213] Examples of diseases described in the present invention include, but are not limited to, genetic diseases, circulatory system diseases, muscle diseases, brain, central nervous and immune system diseases, Alzheimer's disease, secretase disorders, amyotrophic lateral sclerosis (ALS), autism, trinucleotide repeat expansion disorders, hearing diseases, gene targeted therapy of non-dividing cells (neurons, muscles), liver and kidney diseases, epithelial cell and lung diseases, cancer, Usher syndrome or retinitis pigmentosa-39, cystic fibrosis, HIV and AIDS, beta thalassemia, sickle cell disease, herpes simplex virus, autism, drug addiction, age-related macular degeneration, schizophrenia. Other diseases treated by correcting point mutations or introducing inactivating mutations into disease-related genes are known to those skilled in the art, and therefore the present disclosure is not limited in this regard. In addition to the diseases exemplarily described in the present invention, other related diseases can also be treated with the strategies and fusion proteins provided by the present invention, and the application is obvious to those skilled in the art. The diseases or targets to which the present invention can be applied refer to WO2015089465A1 (PCT / US2014 / 070135), WO2016205711A1 (PCT / US2016 / 038181), WO2018141835A1 (PCT / EP2018 / 052491), WO2020191234A1 (PCT / US2020 / 023713), WO2020191233A1 (PCT / US2020 / 023712), WO2019079347A1 (PCT / US2018 / 056146), and WO2021155065A1 (PCT / US2021 / 015580) for the related diseases to which the base editing systems are applicable.
[0214] The administration of the base editing system or pharmaceutical composition of the present invention can be adjusted according to the weight and species of the patient or subject. The frequency of administration is within the range permitted by medicine or veterinary medicine. It depends on conventional factors including the age, sex, general health, other conditions of the patient or subject, and the specific condition or symptom being addressed.
[0215] IX. Test kit
[0216] The present invention also includes a kit for the method of the present invention, the kit comprising the genome editing system of the present invention, and instructions for use. The kit generally includes a label indicating the intended use and / or method of use of the contents of the kit. The term label includes any written or recorded material provided on or with the kit or otherwise provided with the kit.
[0217] Example
[0218] Example 1: Acquisition of a novel adenosine deaminase
[0219] The inventors used bioinformatics technology and all sequences in the public database that were functionally annotated and related to TAD (tRNAadenine deaminase), and obtained 91 candidate proteins through sequence filtering, protein structure analysis using the AlphaFold2 algorithm, and TMalign structure alignment. Among them, a potential adenosine deaminase QB34 (SEQID NO: 4) was included. Blast results showed that the new deaminase protein had a low amino acid sequence similarity with the reported wild-type TadA (SEQID NO: 1) and TadA-8e (SEQ ID NO: 2) with DNA deamination. The sequence similarity comparison results are shown in Figure 1 The amino acid sequence of QB34 is 40.0% identical to TadA, and the amino acid sequence of QB34 is 35.2% identical to TadA-8e.
[0220] Example 2: DNA editing function of QB34 adenosine deaminase
[0221] To verify whether the above-mentioned adenosine deaminase can produce an editing effect on DNA in cells. In this example, an adenine base editor based on 91 candidate proteins including QB34 adenosine deaminase was constructed (the amino acid sequence of QB34 adenine base editor is shown in SEQ ID NO: 20). The schematic diagram of the expression construct structure of QB34 adenine base editor is shown in Figure 2 . sgRNA was designed targeting the genome of human embryonic kidney cells 293T (HEK293T), targeting the site3 (SEQID NO: 15) site of the genomic target DNA. HEK293T cells were transfected with adenine base editors based on candidate proteins, and DNA was extracted 72 hours after transfection; the mock group was used as a blank control without transfection of adenine editor plasmid, and other treatments were the same as above. The base editing efficiency of the target was detected by second-generation sequencing technology. The results showed that among the 91 verified candidate proteins, QB34 showed significant editing efficiency compared with the blank control group (Table 1).
[0222] Table 1 Base editing efficiency of adenine base editors of candidate proteins at site 3
[0223]
[0224] Subsequently, the inventors designed sgRNA targeting the human embryonic kidney cell 293T (HEK293T) genome, targeting the site1 (SEQ ID NO: 14) site of the genomic target DNA. The adenine base editor based on QB34 adenosine deaminase was transfected into HEK293T cells, and DNA was extracted 72 hours after transfection; the mock group was used as a blank control without transfection of the adenine editor plasmid, and other treatments were the same as above. The above results show that the editing efficiency of QB34 adenosine deaminase at the site1 target site is 0.75%, and the editing efficiency at the site3 target site is 1.44% ( Figure 3 ).
[0225] Further analysis of the editing window showed that the editing sites of QB34 adenosine deaminase at site 1 include A2, A4, A5, A6, A9, A11, and A12; the editing sites at site 3 include A2, A3, A5, A7, A8, A9, A12, A14, and A16 ( Figure 4 , Figure 5 ), with a wider editing window.
[0226] In addition, the inventors compared QB34 adenosine deaminase with wild-type TadA adenosine deaminase ( Figure 6-Figure 8 ), the results showed that the editing efficiency of wild-type TadA as a tRNA adenosine deaminase in DNA was close to 0, while the editing efficiency of QB34 was significantly higher than that of TadA ( Figure 6 ). Compare the editing windows of the two adenosine deaminases at site 1 and site 3 ( Figure 7-Figure 8 ), the editing efficiency of TadA at each editing site of QB34 that has editing ability is less than 0.1%, and most of them are even close to 0.
[0227] This shows that QB34 has the function of DNA adenosine deaminase and can serve as a potential deaminase element of adenine base editor.
[0228] Example 3: Optimizing the DNA editing function of QB34 adenosine deaminase
[0229] Screening was performed in the E. coli evolution system, and it was found that the variant QB34C (SEQ ID NO: 5) obtained by extending 8 amino acids at the C-terminus of QB34 can improve the editing efficiency of QB34 deaminase on DNA. These 8 amino acids are derived from the original coding frame of QB34. On this basis, QB34C was mutated to key sites such as W71Y, A91T, V80T and S122G, and the mutations were combined to test whether the editing efficiency of QB34 deaminase on DNA can be further improved. The expression construct structure and fusion protein sequence of the base editor are shown in Table 2, and the preparation method is shown in Example 2.
[0230] The same method as in Example 2 was used to construct an ABE system based on nCas9 nickase (Cas9 (D10A)). The base editing efficiency of QB34C and QB34C mutant adenine base editors on HEK293T cells at the targets of site1, site3, site4 (SEQ ID NO: 18), and site10 (SEQ ID NO: 19) was detected. The results of the second-generation sequencing technology showed that the editing efficiency of QB34C at the target site3 was 1.83%, and the editing efficiency of the single mutant QB34C-W71Y based on QB34C was also slightly improved compared to QB34C. It can be seen that mutating the key sites of QB34C can improve the editing efficiency ( Fig. 9 ).
[0231] The inventors combined single mutation sites and found that the QB34C double mutant had comparable or significantly improved editing efficiency compared to QB34C. For example, the double mutant QB34C-W71Y-S122G mutant had an editing efficiency of up to 21.82% at the site 3 target site. In addition, the QB34C-W71Y-S122G mutant had an editing efficiency of 5.61% at the site 1 target site, 20.53% at the site 4 target site, and 18.1% at the site 10 target site. Fig. 9 ). It can be seen that extending the C-terminus of QB34 adenosine deaminase and single mutants or multiple mutants containing W71Y, A91T, V80T and S122G significantly improve the editing efficiency of DNA and have higher editing activity.
[0232] In addition, QB34, QB34C and their mutants have lower indel (random insertion / deletion) frequencies than existing adenosine deaminases, and their indel frequencies are all lower than 0.2% (Table 3). The results show that when the QB34 series adenosine deaminases are used as the deaminase domain of the base editor to perform deamination editing on specific bases, the frequency of random base insertion / deletion is low, that is, other types of non-target editing are not introduced or are less introduced. In summary, the QB34 series adenosine deaminases have the characteristics of high specificity and high editing safety compared to the adenosine deaminases in the prior art.
[0233] The inventors further analyzed the editing window of QB34 functional variants. Fig.10It shows that for the site3 target, the editing sites of QB34 and QB34C include A2, A3, A5, A7, and A8; in comparison, the base editors corresponding to the QB34C-W71Y single mutant and QB34C-W71Y-S122G, QB34C-W71Y-A91T, and QB34C-W71Y-V80T double mutants only include A2, A3, A5, and A7 in the site3 target window, indicating that the QB34C mutant has a narrower editing window when editing, which is beneficial to improve the accuracy of base editing.
[0234] Figure 11-Figure 12 The editing status of the target sites of site4 and site10 are shown respectively. The results show that the editing sites of the QB34C-W71Y-S122G mutant at the target site4 include A5 and A9, and the editing sites at the target site10 include A5 ( Figure 11-Figure 12 ), especially at site 10, only one site was edited and the editing efficiency was high. The above results show that the QB34C-W71Y-S122G double mutant has a narrower editing window and higher editing activity, reflecting its potential in precise gene editing.
[0235] Table 2 QB34-based and optimized QB34 adenosine deaminase editor fusion protein framework structure and amino acid sequence
[0236]
[0237] Table 3 Indel efficiency of adenosine deaminase editor based on QB34 and optimized QB34
[0238]
[0239] Example 4: DNA editing function of QB34C adenosine deaminase dimer
[0240] In this example, QB34C adenosine deaminase and a preferred mutant constitute a deaminase dimer, and the dimer is used as the adenosine deaminase domain to be connected to the adenine base editor. The framework structure and amino acid sequence of the QB34C dimer base editor fusion protein are shown in Table 2, and the schematic diagram of the expression construct structure is shown in Figure 2 .
[0241] The results showed that the QB34C adenosine deaminase dimer forms could further improve the DNA editing efficiency. The double mutant dimer of (QB34C-W71Y-S122G)-(QB34C-W71Y-S122G) had the highest editing efficiency, with an editing efficiency of 16.46% at the site 1 target, 42.33% at the site 3 target, and 31.59% at the site 10 target. Fig.13 ), the editing efficiency was nearly 3 times higher than that of the (QB34C-W71Y)-(QB34C-W71Y) single mutant dimer. In addition, both the (QB34C-W71Y-S122G)-(QB34C-W71Y-S122G) double mutant dimer and the single mutant dimer introduced lower levels of indel (Table 3), indicating that the deaminase dimer has higher specificity and safety. Further analysis of its editing window revealed that the QB34C adenosine deaminase dimer form contains editing sites A2, A4, A5, A6, and A9 at the site1 target site ( Fig.14 ), the editing window at site3 contains the editing sites A2, A3, A5, and A7 ( Fig.15 ), the editing window at the target site 10 contains A5 ( Fig.16 ), it can be seen that the adenosine deaminase dimer also has the same editing window as its adenosine deaminase.
[0242] In summary, the QB34C adenosine deaminase dimer has improved editing activity while maintaining its precision and safety when used as the deaminase domain of the base editor.
[0243] Some of the sequences involved in this disclosure:
[0244] >SEQ ID NO:1TadA
[0245] MSEVEFSHEYWMRHALTLAKRAWDEREVPVGAVLVHNNRVIGEGWNRPIGRHDPTAHAEIMAL
[0246] RQGGLVMQNYRLIDATLYVTLEPCVMCAGAMIHSRIGRVVFGARDAKTGAAGSLMDVLHHPGM
[0247] NHRVEITEGILADECAALLSDFFRMRRQEIKAQKKAQSSTD
[0248] >SEQ ID NO:2TadA-8e
[0249] MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALR
[0250] QGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNSKRGAAGSLMNVLNYPGMN
[0251] HRVEITEGILADECAALLCDFYRMPRQVFNAQKKAQSSINSGGSSGGSSGSETPGTSESATPESSGG
[0252] SSGGS
[0253] >SEQ ID NO:3TadA*7.10
[0254] MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALR
[0255] QGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMN
[0256] HRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD
[0257] >SEQ ID NO:4QB34
[0258] MKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIMEA
[0259] CEYLGSWRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQVE
[0260] IRSGVKENECQQLLKQFFKRVRKARKAA
[0261] >SEQ ID NO:5QB34C
[0262] MKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIMEA
[0263] CEYLGSWRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQVE
[0264] IRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKN
[0265] >SEQ ID NO:6QB34C-W71Y
[0266] MKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIMEA
[0267] CEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQVEI
[0268] RSGVKENECQQLLKQFFKRVRKARKAARKSAQQKN
[0269] >SEQ ID NO:7QB34C-W71Y-A91T
[0270] MKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIMEA
[0271] CEYLGSYRLEECDLYVTLEPCMMCSGTIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQVEI
[0272] RSGVKENECQQLLKQFFKRVRKARKAARKSAQQKN
[0273] >SEQ ID NO:8QB34C-W71Y-V80T
[0274] MKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIMEA
[0275] CEYLGSYRLEECDLYTTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQVEI
[0276] RSGVKENECQQLLKQFFKRVRKARKAARKSAQQKN
[0277] >SEQ ID NO:9QB34C-W71Y-S122G
[0278] MKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIMEA
[0279] CEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDGRFNHQVE
[0280] IRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKN
[0281] >SEQ ID NO:10(QB34C)-(QB34C-W71Y)
[0282] MKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIMEA
[0283] CEYLGSWRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQVE
[0284] IRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSGGSSGSETPGTSESATPESSGGSSG
[0285] GSKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIME
[0286] ACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQV
[0287] EIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKN
[0288] >SEQ ID NO:11(QB34C-W71Y)-(QB34C)
[0289] MKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIMEA
[0290] CEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQVEI
[0291] RSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSGGSSGSETPGTSESATPESSGGSSG
[0292] GSKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIME
[0293] ACEYLGSWRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQV
[0294] EIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKN
[0295] >SEQ ID NO:12(QB34C-W71Y)-(QB34C-W71Y)
[0296] MKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIMEA
[0297] CEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQVEI
[0298] RSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSGGSSGSETPGTSESATPESSGGSSG
[0299] GSKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIME
[0300] ACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDSRFNHQV
[0301] EIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKN
[0302] >SEQ ID NO:13(QB34C-W71Y-S122G)-(QB34C-W71Y-S122G)
[0303] MKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIMEA
[0304] CEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDGRFNHQVE
[0305] IRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSGGSSGSETPGTSESATPESSGGSSG
[0306] GSKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMRERFQNAAYHAELLAIME
[0307] ACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGTVESLYHLLSDGRFNHQV
[0308] EIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKN
[0309] >SEQ ID NO:14 site1(HEK293T)
[0310] GACAAACCAGAAGCCGCTCC
[0311] >SEQ ID NO:15 site3(HEK293T)
[0312] GAACACAAAGCATAGACTGC
[0313] >SEQ ID NO:16 SpCas9
[0314] MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR
[0315] TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY
[0316] PTIYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE
[0317] NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ
[0318] LSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD
[0319] LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED
[0320] LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW
[0321] MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY
[0322] VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYH
[0323] DLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRIEMIEERLKTYAHLFDDKVMKQLKRRRYTGWGR
[0324] LSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLA
[0325] GSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEGIGELGSQ
[0326] ILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTR
[0327] SDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAEGGGLSELDKAGFIKRQLVE
[0328] TRQITKHVAQILDSRMNTKYDENDKLIVEKVITLSKLVSDFRKDFQFYKVREINNYHHAHDAY
[0329] LNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFKTEITLAN
[0330] GEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIA
[0331] RKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKG
[0332] YKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED
[0333] NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLG
[0334] APAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD
[0335] >SEQ ID NO:17 nCas9(D10A)
[0336] MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKR
[0337] TARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKY
[0338] PTIYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEE
[0339] NPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQ
[0340] LSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD
[0341] LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRED
[0342] LLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW
[0343] MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY
[0344] VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYH
[0345] DLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRIEMIEERLKTYAHLFDDKVMKQLKRRRYTGWGR
[0346] LSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLA
[0347] GSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEGIGELGSQ
[0348] ILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTR
[0349] SDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAEGGGLSELDKAGFIKRQLVE
[0350] TRQITKHVAQILDSRMNTKYDENDKLIVEKVITLSKLVSDFRKDFQFYKVREINNYHHAHDAY
[0351] LNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFKTEITLAN
[0352] GEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIA
[0353] RKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKG
[0354] YKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED
[0355] NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLG
[0356] AP
[0357] >SEQ ID NO:18 site4(HEK293T)
[0358] GAAGACCAAGGATAGACTGC
[0359] >SEQ ID NO:19 site10(HEK293T)
[0360] CTTGACCAATAGCCTTGACA
[0361] >SEQ ID NO:20 QB34-ABE
[0362] MKRTADGSEFSPKKKRKVKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMR
[0363] ERFQNAAYHAELLAIMEACEYLGSWRLEECDLYVTLEPCMMCSGAIMNSRIRTLYGAKNPKAG
[0364] TVESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARAKAASGGSSGGSSGSETPGTSES
[0365] ATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDS
[0366] GETAEATRLKRTARRRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNI
[0367] VDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQL
[0368] VQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSN
[0369] FDLAEDAKLQLSKDTYDDLDLNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASM
[0370] IKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTE
[0371] ELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPL
[0372] ARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTV
[0373] YNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
[0374] RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRIEMIEERLKTYAHLFDDKVMKQL
[0375] KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQG
[0376] DSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMK
[0377] RIEEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLK
[0378] DDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELD
[0379] KAGFIKRQLVETRQITKHVAQILDSRMNTKYENDKLIREVKVITLSKLVSDFRKDFQFYKVREI
[0380] NNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNI
[0381] MNFFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKE
[0382] SILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSF
[0383] EKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLAS
[0384] HYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA
[0385] ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSGGSKR
[0386] TADGSEFEPKKKRKV
[0387] >SEQ ID NO:21 QB34C-ABE
[0388] MKRTADGSEFSPKKKRKVKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMR
[0389] ERFQNAAYHAELLAIMEACEYLGSWRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAG
[0390] TVESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSSGGSSG
[0391] SETPGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKN
[0392] LIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKK
[0393] HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNS
[0394] DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSL
[0395] GLTPNFKSNFDLAEDAKLQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEI
[0396] TKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKP
[0397] ILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTF
[0398] RIPYYVGPLARGNSRFAWMTRKSEEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKH
[0399] SLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD
[0400] VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFD
[0401] DKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQ
[0402] KAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQ
[0403] KNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVD
[0404] HIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAE
[0405] RGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLSKLVSDFRKDF
[0406] QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA
[0407] KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV
[0408] QTGGFSKESILPKRNSDKLIARKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
[0409] ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKY
[0410] VNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHR
[0411] DKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLG
[0412] GDSGGSKRTADGSEFEPKKKRKV
[0413] >SEQ ID NO:22 QB34C-W71Y-ABE
[0414] MKRTADGSEFSPKKKRKVKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMR
[0415] ERFQNAAYHAELLAIMEACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGT
[0416] VESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSSGGSSGS
[0417] ETPGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNL
[0418] IGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKH
[0419] ERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNSD
[0420] VDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLG
[0421] LTPNFKSNFDLAEDAKLQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEIT
[0422] KAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPI
[0423] LEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTF
[0424] RIPYYVGPLARGNSRFAWMTRKSEEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKH
[0425] SLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD
[0426] VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFD
[0427] DKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQ
[0428] KAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQ
[0429] KNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVD
[0430] HIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAE
[0431] RGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLSKLVSDFRKDF
[0432] QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA
[0433] KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV
[0434] QTGGFSKESILPKRNSDKLIARKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
[0435] ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKY
[0436] VNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHR
[0437] DKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLG
[0438] GDSGGSKRTADGSEFEPKKKRKV
[0439] >SEQ ID NO:23 QB34C-A91T-ABE
[0440] MKRTADGSEFSPKKKRKVKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMR
[0441] ERFQNAAYHAELLAIMEACEYLGSYRLEECDLYVTLEPCMMCSGTIMNSRIRTLYYGAKNPKAGT
[0442] VESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSSGGSSGS
[0443] ETPGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNL
[0444] IGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKH
[0445] ERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNSD
[0446] VDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLG
[0447] LTPNFKSNFDLAEDAKLQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEIT
[0448] KAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPI
[0449] LEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTF
[0450] RIPYYVGPLARGNSRFAWMTRKSEEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKH
[0451] SLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD
[0452] VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFD
[0453] DKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQ
[0454] KAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQ
[0455] KNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVD
[0456] HIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAE
[0457] RGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLSKLVSDFRKDF
[0458] QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA
[0459] KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV
[0460] QTGGFSKESILPKRNSDKLIARKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
[0461] ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKY
[0462] VNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHR
[0463] DKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLG
[0464] GDSGGSKRTADGSEFEPKKKRKV
[0465] >SEQ ID NO:24 QB34C-V80T-ABE
[0466] MKRTADGSEFSPKKKRKVKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMR
[0467] ERFQNAAYHAELLAIMEACEYLGSYRLEECDLYTTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGT
[0468] VESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSSGGSSGS
[0469] ETPGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNL
[0470] IGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKH
[0471] ERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNSD
[0472] VDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLG
[0473] LTPNFKSNFDLAEDAKLQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEIT
[0474] KAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPI
[0475] LEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTF
[0476] RIPYYVGPLARGNSRFAWMTRKSEEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKH
[0477] SLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD
[0478] VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFD
[0479] DKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQ
[0480] KAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQ
[0481] KNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVD
[0482] HIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAE
[0483] RGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLSKLVSDFRKDF
[0484] QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA
[0485] KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV
[0486] QTGGFSKESILPKRNSDKLIARKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
[0487] ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKY
[0488] VNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHR
[0489] DKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSKEVLDATLIHQSITGLYETRIDLSQLG
[0490] GDSGGSKRTADGSEFEPKKKRKV
[0491] >SEQ ID NO:25 QB34C-S122G-ABE
[0492] MKRTADGSEFSPKKKRKVKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMR
[0493] ERFQNAAYHAELLAIMEACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGT
[0494] VESLYHLLSDGRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSSGGSSGS
[0495] ETPGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNL
[0496] IGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKH
[0497] ERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNSD
[0498] VDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLG
[0499] LTPNFKSNFDLAEDAKLQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEIT
[0500] KAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPI
[0501] LEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTF
[0502] RIPYYVGPLARGNSRFAWMTRKSEEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKH
[0503] SLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD
[0504] VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFD
[0505] DKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQ
[0506] KAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQ
[0507] KNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVD
[0508] HIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAE
[0509] RGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLSKLVSDFRKDF
[0510] QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA
[0511] KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV
[0512] QTGGFSKESILPKRNSDKLIARKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
[0513] ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKY
[0514] VNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHR
[0515] DKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSKEVLDATLIHQSITGLYETRIDLSQLG
[0516] GDSGGSKRTADGSEFEPKKKRKV
[0517] >SEQ ID NO:26(QB34C-W71Y-S122G)-(QB34C-W71Y-S122G)-ABE
[0518] MKRTADGSEFSPKKKRKVKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMR
[0519] ERFQNAAYHAELLAIMEACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGT
[0520] VESLYHLLSDGRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSSGGSSGS
[0521] ETPGTSESATPESSGGSSGGSKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNM
[0522] RERFQNAAYHAELLAIMEACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAG
[0523] TVESLYHLLSDGRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSSGGSSG
[0524] SETPGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKN
[0525] LIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKK
[0526] HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNS
[0527] DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSL
[0528] GLTPNFKSNFDLAEDAKLQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEI
[0529] TKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKP
[0530] ILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTF
[0531] RIPYYVGPLARGNSRFAWMTRKSEEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKH
[0532] SLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD
[0533] VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFD
[0534] DKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQ
[0535] KAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQ
[0536] KNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVD
[0537] HIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAE
[0538] RGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLSKLVSDFRKDF
[0539] QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA
[0540] KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV
[0541] QTGGFSKESILPKRNSDKLIARKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
[0542] ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKY
[0543] VNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHR
[0544] DKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSKEVLDATLIHQSITGLYETRIDLSQLG
[0545] GDSGGSKRTADGSEFEPKKKRKV
[0546] >SEQ ID NO:27(QB34C-W71Y)-(QB34C-W71Y)-ABE
[0547] MKRTADGSEFSPKKKRKVKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMR
[0548] ERFQNAAYHAELLAIMEACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGT
[0549] VESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSSGGSSGS
[0550] ETPGTSESATPESSGGSSGGSKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNM
[0551] RERFQNAAYHAELLAIMEACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAG
[0552] TVESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSSGGSSG
[0553] SETPGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKN
[0554] LIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKK
[0555] HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNS
[0556] DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSL
[0557] GLTPNFKSNFDLAEDAKLQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEI
[0558] TKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKP
[0559] ILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTF
[0560] RIPYYVGPLARGNSRFAWMTRKSEEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKH
[0561] SLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD
[0562] VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFD
[0563] DKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQ
[0564] KAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQ
[0565] KNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVD
[0566] HIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAE
[0567] RGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLSKLVSDFRKDF
[0568] QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA
[0569] KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV
[0570] QTGGFSKESILPKRNSDKLIARKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
[0571] ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKY
[0572] VNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHR
[0573] DKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLG
[0574] GDSGGSKRTADGSEFEPKKKRKV
[0575] >SEQ ID NO:28(QB34C)-(QB34C-W71Y)-ABE
[0576] MKRTADGSEFESPKKKRKVKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMR
[0577] ERFQNAAYHAELLAIMEACEYLGSWRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAG
[0578] TVESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSGGSSG
[0579] SETPGTSESATPESSGGSSGGSKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNM
[0580] RERFQNAAYHAELLAIMEACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAG
[0581] TVESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSGGSSG
[0582] SETPGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKN
[0583] LIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKK
[0584] HERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNS
[0585] DVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSL
[0586] GLTPNFKSNFDLAEDAKLQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEI
[0587] TKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKP
[0588] ILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTF
[0589] RIPYYVGPLARGNSRFAWMTRKSEEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKH
[0590] SLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFD
[0591] VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFD
[0592] DKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQ
[0593] KAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQ
[0594] KNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVD
[0595] HIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAE
[0596] RGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLSKLVSDFRKDF
[0597] QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA
[0598] KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV
[0599] QTGGFSKESILPKRNSDKLIARKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLG
[0600] ITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKY
[0601] VNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHR
[0602] DKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSKEVLDATLIHQSITGLYETRIDLSQLG
[0603] GDSGGSKRTADGSEFEPKKKRKV
[0604] >SEQ ID NO:29(QB34C-W71Y)-(QB34C)-ABE
[0605] MKRTADGSEFESPKKKRKVKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNMR
[0606] ERFQNAAYHAELLAIMEACEYLGSYRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKAGT
[0607] VESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSGGSSGS
[0608] ETPGTSESATPESSGGSSGGSKILQPEDYMEMALAEARQAELMDEVPIGAIVVYHGKVIGAGHNM
[0609] RERFQNAAYHAELLAIMEACEYLGSWRLEECDLYVTLEPCMMCSGAIMNSRIRTLYYGAKNPKA
[0610] GTVESLYHLLSDSRFNHQVEIRSGVKENECQQLLKQFFKRVRKARKAARKSAQQKNSGGSSGGSS
[0611] GSETPGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKK
[0612] NLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDK
[0613] KHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPD
[0614] NSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIAL
[0615] SLGLTPNFKSNFDLAEDAKLQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNT
[0616] EITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFI
[0617] KPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKIL
[0618] TFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPK
[0619] HSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF
[0620] DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLF
[0621] DDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDI
[0622] QKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKG
[0623] QKNSRERMKRIEEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDV
[0624] DHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTK
[0625] AERGGGLSELDKAGFIKRKQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRK
[0626] DFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKA
[0627] TAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTE
[0628] VQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELL
[0629] GITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSK
[0630] YVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKH
[0631] RDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSKEVLDATLIHQSITGLYETRIDLSQLG
[0632] GDSGGSKRTADGSEFEPKKKRKV
[0633] >SEQ ID NO:30 32aa
[0634] SGGSSGGSSGSETPGTSESATPESSGGSSGGS
[0635] >SEQ ID NO:31 NLS
[0636] MKRTADGSFESPKKKRKV
[0637] >SEQ ID NO:32 TraC
[0638] MSVSFSLNAKKIRLENYAMKMRLYPSPTQAEQMDKMFLALRLAYNMTFHEVFQQNPAVCGDPD
[0639] EDGNVWPSYKKMANKTWRKALIDQNPAIEAPAAAITTNNGLFLSNGQKAWKTGMHNLPANKA
[0640] DRKDFRFYSLSKPRRSFAVQIPPDCIIPSDTNQKVARIKLPKIDGAIKARGFNRKIWFGPDGKHTYEE
[0641] ALAAHELSNNLTVRVSKDTCGDYFICITFSQGKVKGDKPTWEFYQEVRVSPIPEPIGLDVGIKDIAIL
[0642] NTGTKYENKQFKRDRAATLKKMSRQLSRRWGPANSAFRDYNKNIRAENRALEKAQQDPGSSGV
[0643] GPEAPVLKSVAQPSRRYLTIQKNRAKLERKIARRRDTYYHQVTAEVAGKSSLLAVETLRVKNMLQ
[0644] NHRLAFALSDAAMSDFISKLKYKARRIQVPLVAIGTFQPSSQTCSVCGSINPAVKNLSIRVWTCPNC
[0645] GTRHNRDINAAKNILAIAQNMLEKKVPFADEALPDEKPPAAPVKKAARKPRDAVFPDHPDLVIRFS
[0646] KELTQLNDPRYVIVNKATNQIVDNAQGAGYRSAAKAKNCYKAKLAWSSKTNK
[0647] >SEQ ID NO:33 NLS
[0648] KKRKV
[0649] >SEQ ID NO:34 NLS
[0650] PKKKRKV
[0651] >SEQ ID NO:35 NLS
[0652] KRPAATKKAGQAKKKK(SEQ ID NO:35)>SEQ ID NO:36 NLSMKRTADGSEFEPKKKRKV
Claims
1. An adenosine deaminase capable of deaminating adenine bases in DNA, wherein the adenosine deaminase is selected from one or more of the following (i) to (iii): (i) comprising an amino acid sequence that is at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:4, and which retains the deamination activity of the amino acid sequence shown in SEQ ID NO:4; (ii) an amino acid sequence comprising consecutive amino acids added to the C-terminus of the amino acid sequence shown in SEQ ID NO: 4, and which retains the deamination activity of the amino acid sequence shown in SEQ ID NO: 4; or (iii) A multimer comprising any two or more amino acid sequences as described in (i) or (ii).
2. The adenosine deaminase according to claim 1, in, In (ii), the adenosine deaminase comprises an amino acid sequence having at least 8 consecutive amino acids added to the C-terminus of SEQ ID NO:
4.
3. The adenosine deaminase according to claim 2, in, In (ii), the adenosine deaminase comprises the amino acid sequence shown in SEQ ID NO:
5.
4. The adenosine deaminase according to any one of claims 1 to 3, in, The adenosine deaminase comprises an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or inserted into the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 5, and retains the deamination activity of the amino acid sequence shown in SEQ ID NO:
4.
5. The adenosine deaminase according to claim 4, in, The adenosine deaminase comprises an amino acid sequence having a W71X mutation in SEQ ID NO: 4 or SEQ ID NO: 5, wherein X is any amino acid except W (tryptophan), preferably, X is Y (tyrosine).
6. The adenosine deaminase according to any one of claims 1 to 5, in, The adenosine deaminase comprises an amino acid sequence having an A91X mutation in SEQ ID NO: 4 or SEQ ID NO: 5, wherein X is any amino acid except A (alanine).
7. The adenosine deaminase according to claim 6, in, X is T (threonine).
8. The adenosine deaminase according to any one of claims 1 to 7, in, The adenosine deaminase comprises an amino acid sequence having a V80X mutation in SEQ ID NO: 4 or SEQ ID NO: 5, wherein X is any amino acid except V (valine).
9. The adenosine deaminase according to claim 8, in, X is T (threonine).
10. The adenosine deaminase according to any one of claims 1 to 9, in, The adenosine deaminase comprises an amino acid sequence having an S122X mutation in SEQ ID NO: 4 or SEQ ID NO: 5, wherein X is any amino acid except S (serine).
11. The adenosine deaminase according to claim 10, in, X is G (glycine).
12. The adenosine deaminase according to any one of claims 1 to 11, in, The adenosine deaminase comprises an amino acid sequence having one or more mutations selected from the group consisting of W71Y mutation, A91T mutation, V80T mutation and S122T mutation in SEQ ID NO: 4 or SEQ ID NO:
5.
13. The adenosine deaminase according to any one of claims 1 to 12, in, The adenosine deaminase comprises an amino acid sequence having a W71Y mutation in SEQ ID NO: 4 or SEQ ID NO: 5 and another mutation of an adenine deaminase.
14. The adenosine deaminase according to any one of claims 1 to 13, in, The adenosine deaminase comprises an amino acid sequence having W71Y and A91T mutations in SEQ ID NO:4 or SEQ ID NO:
5.
15. The adenosine deaminase according to any one of claims 1 to 13, in, The adenosine deaminase comprises an amino acid sequence having W71Y and V80T mutations in SEQ ID NO:4 or SEQ ID NO:
5.
16. The adenosine deaminase according to any one of claims 1 to 13, in, The adenosine deaminase comprises an amino acid sequence having W71Y and S122T mutations in SEQ ID NO:4 or SEQ ID NO:
5.
17. The adenosine deaminase according to any one of claims 1 to 16, in, In (iii), the multimer comprises a dimer consisting of any two amino acid sequences as described in (i) and (ii), and the any two amino acid sequences as described in (i) and (ii) are connected by a linker.
18. The adenosine deaminase according to claim 17, in, The linker comprises the amino acid sequence shown in SEQ ID NO:
30.
19. Use of the adenosine deaminase according to any one of claims 1 to 18 for gene editing in an organism or an organism cell, or use of the adenosine deaminase according to any one of claims 1 to 18 for preparing a reagent for gene editing in an organism or an organism cell.
20. A fusion protein comprising: (a) a nucleic acid targeting domain; and (b) an adenosine deamination domain, wherein the adenosine deamination domain comprises at least one polypeptide of the adenosine deaminase according to any one of claims 1 to 18.
21. The fusion protein according to claim 20, in, The nucleic acid targeting domain is a TALE, ZFP or CRISPR effector protein domain.
22. The fusion protein according to claim 21, in, The CRISPR effector protein is selected from Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9, Cas10, Cast10d, Cas12, Cas13, Cas14, CasX, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (or CasA), Cse2 (or CasB), Cse3 (or CasE ), Cse4 (or CasC), Csc1, Csc2, Csa5, Csn1, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Cpf1, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csz1, Csx15, Csf1, Csf2, Csf3, Csf4, Cu1966, TraC, and their functional variants or any combination thereof.
23. The fusion protein according to any one of claims 20 to 22, in, The nucleic acid targeting domain and the adenosine deamination domain are fused via a linker.
24. The fusion protein according to any one of claims 20 to 22, in, The fusion protein also comprises a nuclear localization sequence (NLS).
25. A base editing system for modifying a target region of a nucleic acid molecule, comprising: i) the adenosine deaminase according to any one of claims 1 to 18 or the fusion protein according to any one of claims 20 to 24, and / or an expression construct containing a nucleotide sequence encoding the adenosine deaminase or the fusion protein.
26. The base editing system according to claim 25, in, The base editing system further comprises: ii) at least one guide RNA and / or at least one expression construct comprising a nucleotide sequence encoding said at least one guide RNA; and / or iii) Nuclear localization sequence (NLS).
27. The base editing system according to claim 26, in, The at least one guide RNA is bound to the nucleic acid targeting domain of the fusion protein, and the guide RNA is directed against at least one target sequence within the target region of the nucleic acid molecule.
28. The base editing system according to claim 27, in, The guide RNA is 15-100 nucleotides in length and comprises a sequence of at least 10, at least 15, or at least 20 consecutive nucleotides that are complementary to the target sequence.
29. The base editing system according to claim 28, in, The guide RNA comprises a 15 to 40 consecutive nucleotide sequence complementary to the target sequence.
30. The base editing system according to any one of claims 26 to 29, in, The guide RNA has a length of 15-50 nucleotides.
31. The base editing system according to any one of claims 26 to 30, in, The nucleic acid molecule is DNA.
32. The base editing system according to any one of claims 26 to 31, in, The nucleic acid molecule is in the genome of an organism.
33. The base editing system of claim 32, in, The organism is a prokaryotic organism such as a bacterium; a eukaryotic organism such as a plant, a fungus or a vertebrate.
34. The base editing system of claim 33, in, The vertebrate is a mammal such as a human, mouse, rat, monkey, dog, pig, sheep, cow, or cat.
35. The base editing system of claim 33, in, The plant is a crop plant, for example wheat, rice, corn, soybean, sunflower, sorghum, rapeseed, alfalfa, cotton, barley, millet, sugarcane, tomato, kiwifruit, lettuce, tobacco, cassava or potato.
36. A base editing method, in, The base editing method comprises contacting the base editing system of any one of claims 25-35 with a nucleic acid molecule target sequence.
37. The base editing method according to claim 36, in, The nucleic acid molecule is a double-stranded DNA molecule or a single-stranded DNA molecule.
38. The base editing method according to any one of claims 36-37, in, The nucleic acid molecule target sequence comprises a sequence associated with plant traits or expressions.
39. The base editing method according to any one of claims 36-37, in, The nucleic acid molecule target sequence comprises a sequence or point mutation associated with a disease or disorder.
40. The base editing method according to any one of claims 36 to 39, in, The base editing system contacts a target sequence of a nucleic acid molecule and exerts a deamination effect, which causes one or more nucleotides in the target sequence to be replaced.
41. The base editing method according to any one of claims 36 to 40, in, The target sequence comprises a DNA sequence 5'-MAN-3', wherein M is A, T, C or G; N is A, T, C or G; and A in the middle of the 5'-MAN-3' sequence is deaminated.
42. The base editing method according to any one of claims 36 to 41, in, The deamination results in the introduction or removal of a splice site.
43. The base editing method according to any one of claims 36 to 42, in, The deamination results in the introduction of mutations in the gene promoter, which result in increased or decreased transcription of a gene operably linked to the gene promoter.
44. The base editing method according to any one of claims 36 to 43, in, The deamination results in the introduction of mutations in the gene suppressor that result in increased or decreased transcription of a gene operably linked to the gene suppressor.
45. The base editing method according to any one of claims 36 to 44, in, The contacting is performed in vivo or wherein the contacting is performed in vitro.
46. A method for producing at least one genetically modified cell, comprising introducing the base editing system of any one of claims 25-35 into at least one of the cells, thereby causing one or more nucleotides in the target nucleic acid region in the at least one cell to be replaced, wherein the one or more nucleotide replacements are A to G replacements.
47. The method according to claim 46, in, The method further comprises the step of screening the at least one cell for cells having the desired one or more nucleotide substitutions.
48. The method according to claim 46 or 47, in, The base editing system is introduced into cells by a method selected from the following: calcium phosphate transfection, protoplast fusion, electroporation, liposome transfection, microinjection, viral infection (such as baculovirus, vaccinia virus, adenovirus, adeno-associated virus, lentivirus or other virus), N-acetylgalactosamine (GalNAc) mediation, gene gun method, PEG-mediated protoplast transformation, soil Agrobacterium-mediated transformation.
49. The method according to any one of claims 46 to 48, in, The cells are from mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cattle, cats; poultry such as chickens, ducks, geese; plants, preferably crop plants, such as wheat, rice, corn, soybeans, sunflowers, sorghum, rapeseed, alfalfa, cotton, barley, millet, sugarcane, tomatoes, kiwifruit, lettuce, tobacco, cassava and potatoes.
Citation Information
Cited By
Excavation of natural deoxyadenosine deaminase based on adjacent domain annotation and key amino acid residue site alignment
CN121046356A
Novel CRISPR gene editing system
CN122303193A
